Company / Cash & Equivalents
Protagonist Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$128.4M
FY2025
5-year range
$97.2M / $186.7M
FY2021-FY2025
Trend
+32.0%
vs FY2024
Sector context
#125 of 207
Health Care
What the data says
At $128M, Protagonist Therapeutics, Inc.'s cash & equivalents ranks #125 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $21M in FY2016 to $187M in FY2023.
Based on SEC 10-K filings.
$128M in FY2025 with a 5-year CAGR of +1.8%.
Declined from $187M to $128M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Sector benchmark
#125 of 207 in Health CareTop 60% of 207This company $128.4M Sector average $669.5M
▼
-80.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 32.0% year-over-year.
- Ranks #125 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $128.4M | +32.0% |
| FY2024 | $97.2M | -47.9% |
| FY2023 | $186.7M | +48.5% |
| FY2022 | $125.7M | +1.7% |
| FY2021 | $123.7M | +5.4% |
| FY2020 | $117.4M | +255.6% |
| FY2019 | $33.0M | -59.9% |
| FY2018 | $82.2M | -22.4% |
| FY2017 | $106.0M | +402.9% |
| FY2016 | $21.1M | +420.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026